Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Testing effectiveness (Phase 2)Ended earlyNCT04240002
What this trial is testing

Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Astellas Pharma Global Development, Inc. 9
Testing effectiveness (Phase 2)UnknownNCT05241106
What this trial is testing

HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc. 15
Early research (Phase 1)Looking for participantsNCT05445011
What this trial is testing

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 12
Testing effectiveness (Phase 2)Ended earlyNCT04209725
What this trial is testing

CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
SCRI Development Innovations, LLC 1
Testing effectiveness (Phase 2)Study completedNCT01349049
What this trial is testing

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 90
Testing effectiveness (Phase 2)Ended earlyNCT00866281
What this trial is testing

The Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Novartis Pharmaceuticals 22
Large-scale testing (Phase 3)Study completedNCT02039726
What this trial is testing

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Who this might be right for
AML
Daiichi Sankyo 367
Testing effectiveness (Phase 2)UnknownNCT05241093
What this trial is testing

HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc. 18
Testing effectiveness (Phase 2)Study completedNCT01565668
What this trial is testing

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo 76
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Testing effectiveness (Phase 2)UnknownNCT05023707
What this trial is testing

Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University 5
Very early researchUnknownNCT05432401
What this trial is testing

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 18
Early research (Phase 1)Ended earlyNCT03552029
What this trial is testing

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03793478
What this trial is testing

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 65
Testing effectiveness (Phase 2)Study completedNCT01892371
What this trial is testing

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
FLT3 Gene Mutation NegativeFLT3 Internal Tandem Duplication PositiveRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center 73
Early research (Phase 1)WithdrawnNCT03904069
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Amgen